238 related articles for article (PubMed ID: 26546771)
1. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
[TBL] [Abstract][Full Text] [Related]
2. Inclusion/exclusion criteria in late life depression antidepressant efficacy trials.
Zimmerman M; Multach MD; Clark HL; Walsh E; Rosenstein LK; Gazarian D
Int J Geriatr Psychiatry; 2017 Sep; 32(9):1009-1016. PubMed ID: 27546477
[TBL] [Abstract][Full Text] [Related]
3. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.
Zimmerman M; Holst CG; Clark HL; Multach M; Walsh E; Rosenstein LK; Gazarian D
CNS Drugs; 2016 Dec; 30(12):1209-1218. PubMed ID: 27541608
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
5. Symptom Severity and the Generalizability of Antidepressant Efficacy Trials: Changes During the Past 20 Years.
Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
J Clin Psychopharmacol; 2016 Apr; 36(2):153-6. PubMed ID: 26848791
[TBL] [Abstract][Full Text] [Related]
6. Have Treatment Studies of Depression Become Even Less Generalizable? A Review of the Inclusion and Exclusion Criteria Used in Placebo-Controlled Antidepressant Efficacy Trials Published During the Past 20 Years.
Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
Mayo Clin Proc; 2015 Sep; 90(9):1180-6. PubMed ID: 26276679
[TBL] [Abstract][Full Text] [Related]
7. Has the symptom severity inclusion requirement narrowed the definition of major depressive disorder in antidepressant efficacy trials?
Zimmerman M; Walsh E; Chelminski I; Dalrymple K
J Affect Disord; 2017 Mar; 211():60-64. PubMed ID: 28088058
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
12. Have Treatment Studies of Depression Become Even Less Generalizable? Applying the Inclusion and Exclusion Criteria in Placebo-Controlled Antidepressant Efficacy Trials Published over 20 Years to a Clinical Sample.
Zimmerman M; Balling C; Chelminski I; Dalrymple K
Psychother Psychosom; 2019; 88(3):165-170. PubMed ID: 31096246
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
[TBL] [Abstract][Full Text] [Related]
15. Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.
Zimmerman M; Balling C; Chelminski I; Dalrymple K
J Affect Disord; 2020 Jan; 260():483-488. PubMed ID: 31539683
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
17. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
19. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included.
Zimmerman M; Chelminski I; Posternak MA
J Nerv Ment Dis; 2004 Feb; 192(2):87-94. PubMed ID: 14770052
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
